Skip to main content
Premium Trial:

Request an Annual Quote

Janet Rowley Dies

Cancer geneticist Janet Rowley has died, the Associated Press reports. She was 88. Working at the University of Chicago, Rowley studied leukemia and connected the disease to genetic aberrations. In particular, she uncovered translocations within leukemic cells. The AP notes that this discovery led to new treatments for leukemia.

"Janet Rowley's work established that cancer is a genetic disease," said the University of Washington's Mary-Claire King in a statement issued by the University of Chicago. "She demonstrated that mutations in critical genes lead to specific forms of leukemia and lymphoma, and that one can determine the form of cancer present in a patient directly from the genetic changes in the cancer. We are still working from her paradigm."

Rowley has received National Medal of Science as well as the Presidential Medal of Freedom.

"I've never regretted being in science and being in research," Rowley said upon receiving the presidential award in 2009. "The exhilaration that one gets in making new discoveries is beyond description."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.